DURAGESIC-25
LOE ApproachingNDATRANSDERMALFILM, EXTENDED RELEASE
Approved
Aug 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DURAGESIC-25 is a transdermal extended-release film formulation of fentanyl, a potent opioid analgesic. It delivers 25 micrograms per hour of fentanyl through the skin for chronic pain management. The mechanism of action involves mu-opioid receptor agonism in the central and peripheral nervous systems.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30% intensity), suggesting the brand team is likely focused on lifecycle management and defending market position against generics.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on DURAGESIC-25 offers limited growth trajectory given its LOE-approaching status and low linked job count. This role is best suited for professionals interested in lifecycle management, managed care navigation, or defensive brand strategy rather than launch or expansion.
Brand ManagerField Sales Representative
Worked on DURAGESIC-25 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.